Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||GSK3359609 + Tremelimumab|
GSK3359609 is an antibody that binds to the inducible T-cell co-stimulator, resulting in stimulation of T-cell proliferation and immune response (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GSK3359609||GSK609|GSK-3359609|GSK 3359609|feladilimab||GSK3359609 is an antibody that binds to the inducible T-cell co-stimulator (ICOS, CD278), resulting in stimulation of T-cell proliferation and immune response (AACR Annual Meeting 2019, Abstract CT166, PMID: 31847708).|
|Tremelimumab||Imjudo||CP-675,206|Ticilimumab|CP-675206||CTLA4 Antibody 28 Immune Checkpoint Inhibitor 146||Imjudo (tremelimumab) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937). Imjudo (tremelimumab) is FDA approved for use in combination with Imfinzi (durvalumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with Imfinzi (durvalumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03693612||Phase Ib/II||GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab||GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors||Completed||USA | CAN | AUS||0|